Evidence map›Paper›PMID 40033430›Full record

ArticleGenome medicine2025

Non-coding cis-regulatory variants in HK1 cause congenital hyperinsulinism with variable disease severity.

Jasmin J Bennett, Cécile Saint-Martin, Bianca Neumann, Jonna M E Männistö, Jayne A L Houghton, Susann Empting, Matthew B Johnson, Thomas W Laver, Jonathan M Locke, Benjamin Spurrier and 13 more

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jasmin J Bennett *Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Cécile Saint-Martin *Department of Medical Genetics, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, 75013, Paris, France.
Bianca Neumann *Institute of Human Genetics, University Hospital, Otto-Von-Guericke University Magdeburg, Leipziger Str. 44, Magdeburg, 39120, Germany.
Jonna M E Männistö *Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Jayne A L HoughtonDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Susann EmptingChildren's University Hospital, Otto-Von-Guericke University Magdeburg, Leipziger Str. 44, Magdeburg, 39120, Germany.
Matthew B JohnsonDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Thomas W LaverDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Jonathan M LockeDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Benjamin SpurrierDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Matthew N WakelingDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Indraneel BanerjeeDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, M13 9WL, UK.
Antonia DastamaniEndocrinology Department, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK.
Hüseyin DemirbilekFaculty of Medicine, Department of Pediatric Endocrinology, Hacettepe University, Ankara, Turkey.
John MitchellPediatric Endocrinology and Biochemical Genetics, Human Genetics and Pediatrics, Montreal Children's Hospital-McGill University, McGill University, Montreal, Canada.
Markus StangeDepartment of Pediatrics, University Hospital Halle, Ernst Grube Str. 40, Halle, 06120, Germany.
International Congenital Hyperinsulinism Consortium
Klaus MohnikeChildren's University Hospital, Otto-Von-Guericke University Magdeburg, Leipziger Str. 44, Magdeburg, 39120, Germany.
Jean-Baptiste ArnouxReference Center for Inherited Metabolic Diseases, Necker-Enfants-Malades University Hospital, APHP, Imagine Institute, G2M, MetabERN, Paris Cité University, Paris, 75015, France.
Nick D L OwensDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK.
Martin ZenkerInstitute of Human Genetics, University Hospital, Otto-Von-Guericke University Magdeburg, Leipziger Str. 44, Magdeburg, 39120, Germany.
Christine Bellanné-ChantelotDepartment of Medical Genetics, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, 75013, Paris, France.
Sarah E FlanaganDepartment of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, EX2 5DW, UK. S.Flanagan@exeter.ac.uk.

Funding

Wellcome 223187/Z/21/ZWellcome Trust
6 · The paper itself

Abstract

backgroundWe recently reported non-coding variants in a cis-regulatory element of the beta-cell disallowed gene hexokinase 1 (HK1) as a novel cause of congenital hyperinsulinism. These variants lead to a loss of repression of HK1 in pancreatic beta-cells, causing insulin secretion during hypoglycaemia. In this study, we aimed to determine the prevalence, genetics, and phenotype of HK1-hyperinsulinism by screening a large international cohort of patients living with the condition.

methodsWe screened the HK1 cis-regulatory region in 1761 probands with hyperinsulinism of unknown aetiology who had been referred to one of three large European genomics laboratories.

resultsWe identified a HK1 variant in 89/1761 probands (5%) and 63 family members. Within the Exeter HI cohort, these variants accounted for 2.8% of all positive genetic diagnoses (n = 54/1913) establishing this as an important cause of HI. Individuals with a disease-causing variant were diagnosed with hyperinsulinism between birth and 26 years (median: 7 days) with variable response to treatment; 80% were medically managed and 20% underwent pancreatic surgery due to poor response to medical therapy. Glycaemic outcomes varied from spontaneous remission to hypoglycaemia persisting into adulthood. Eight probands had inherited the variant from a parent not reported to have hyperinsulinism (median current age: 39 years), confirming variable penetrance. Two of the 23 novel HK1 variants allowed us to extend the minimal cis-regulatory region from 42 to 46 bp.

conclusionsNon-coding variants within the HK1 cis-regulatory region cause hyperinsulinism of variable severity ranging from neonatal-onset, treatment-resistant disease to being asymptomatic into adulthood. Discovering variants in 89 families confirms HK1 as a major cause of hyperinsulinism and highlights the important role of the non-coding genome in human monogenic disease.

Indexed as

Congenital HyperinsulinismGenetic VariationHexokinaseAdolescentAdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornMalePhenotypeSeverity of Illness IndexYoung AdultHexokinaseHK1 protein, humanCongenital hyperinsulinismHexokinase 1Monogenic diseaseNon-codingVariable penetrance

Identifiers

PMID40033430
PMCPMC11874398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.